At a compound annual growth rate of 3.84%, the size of the worldwide Urodynamic Equipment market is projected to reach USD 284.98 Mn in 2028.
The global urodynamic equipment market was valued at USD 311.2 million in 2020 and is projected to grow at a CAGR of 6.6% during the forecast period. Factors driving the growth of the urodynamic equipment market include rising prevalence of diseases such as benign prostatic hypertrophy, bladder cancer, neurogenic bladder dysfunction, overactive bladder and technological advancements in urodynamic equipment’s.
The global urodynamic equipment market is segmented based on type, application and end user. On the basis of application, the market is segmented into kidney diseases, cancer diagnostics, and other applications. The kidney diseases segment dominated the market in 2020. On the basis of end user, the market is segmented into hospitals & urology clinics, ambulatory infusion center, and other end users.
Regionally, North America accounted for the largest market share of the global urodynamic equipment market attributable to high adoption rate of urodynamic products. Leading players of the global urodynamic equipment market include Covidien plc, Albyn Medical S.L., Medical Measurement Systems B.V., C. R. Bard, Inc., American Medical Systems, Inc., HealthTronics, Inc., CooperSurgical, Inc., LABORIE, Verathon, Inc. among others.
Urodynamic Equipment Market Scope
Metrics | Details |
Base Year | 2023 |
Historic Data | 2018-2022 |
Forecast Period | 2024-2028 |
Study Period | 2018-2028 |
Forecast Unit | Value (USD) |
Revenue forecast in 2028 | USD 284.98 Mn |
Growth Rate | CAGR of 3.84% during 2018-2028 |
Segment Covered | by Type, by Applications, Regions |
Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
Key Players Profiled | Boston Scientific Corporation, LABORIE, Verathon, Inc., Albyn Medical Ltd., CooperSurgical Inc., SCHIPPERS – MEDIZINTECHNK – BOSCHSTR, Medica SpA, Neomedix Systems Pty. Ltd., Dantec Medical A/S |
Key segments of the global urodynamic equipment market
Type Overview, (USD Million)
- Uroflowmetry Equipment
- Cystometry
- Ambulatory Urodynamic Systems
- Electromyographs
- Video Urodynamic Systems
- Urodynamic Consumables
Application Overview, (USD Million)
- Kidney Diseases
- Cancer
- Other Applications
End User Overview, (USD Million)
- Hospitals & Urology Clinics
- Ambulatory Centers
- Other End Users
Regional Overview, (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Asia Pacific
- China
- Japan
- India
- Latin America
- Middle East & Africa
Reasons for the study
- Rising geriatric population and increasing high incidence of urologic conditions
- Technological advancements in urodynamic equipment
What does the report include?
- The study on the global urodynamic equipment market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of type, application and end user. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global urodynamic equipment market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global urodynamic equipment market
Consultants, analysts, researchers, and academicians looking for insights shaping the global urodynamic equipment market
Frequently Asked Questions (FAQ) :
Urodynamic testing is an important part of the comprehensive evaluation of voiding dysfunction. The clinician must exercise clinical judgment in the appropriate selection of urodynamic tests following an appropriate evaluation and symptom characterization. Urodynamic studies are indicated only after an initial evaluation is performed that, at minimum, includes an appropriate history, physical exam, and urinalysis with microscopy. Infection, if present, should be treated and effectiveness of treatment observed before further diagnostic (urodynamic) testing or other therapeutic interventions are undertaken. Many types of urodynamic testing require urethral catheterization and include cystometry, pressure flow studies (PFS), and urethral function testing. Such testing subjects patients to risks of urethral instrumentation including infection, urethral trauma, and pain. Thus, the clinician must weigh whether urodynamic tests offer additional diagnostic benefit beyond symptom assessment, physical examination, and other diagnostic testing.
On the basis of type, the market is segmented into uroflowmetry equipment, cystometry, ambulatory urodynamic systems, electromyographs, video urodynamic systems and urodynamic consumables. The uroflowmetry segment dominated the market in 2020. Uroflowmetry measures how much urine one makes, and the quality of the urine stream. The quality of the urine stream relates to how strong it is. This can show if one has a hard time getting urine out and emptying the bladder. This might be due to a weak bladder muscle or to some type of blockage of the urethra. For this test, it is asked to arrive with a full bladder. During the test, one will pass urine. The urine flow and how well one is able to empty the bladder are measured.
Asia Pacific is anticipated to observer the fastest growth rate over the forecast period. Bladder cancer is the tenth commonest cancer in Australia, accounting for approximately 2% of all new cancers. In keeping with most other countries, the incidence of bladder cancer in Australia is more than three times higher in men than in women. Unfortunately, bladder cancer is the only cancer in Australia in which survival is worsening; five-year survival has fallen from 68% to 58% in the past 30 years. Of additional concern is the significantly lower five-year survival for women, which is 50%, as compared with 60% in men. In such circumstances, the urodynamic equipment market is set to prosper in the region.